The Cooper Companies

pharma

San Ramon, CA · COO · Public

The Cooper Companies beat Q2 2026 earnings estimates with $1.21 EPS vs. $1.1 consensus, driven by strong CooperVision momentum in EMEA and Americas despite Asia Pacific softness. The company continues navigating litigation charges from embryo culture media recalls that have impacted profitability, while maintaining robust revenue growth across its two core business units.

The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.

Employees

16,000

Mfg Plants

All Facilities

Activity

6/10

Type

Public